StockNews.com Begins Coverage on Cellectis (NASDAQ:CLLS)

Research analysts at StockNews.com initiated coverage on shares of Cellectis (NASDAQ:CLLS) in a report issued on Monday. The firm set a “sell” rating on the biotechnology company’s stock.

Separately, Barclays cut their price target on shares of Cellectis from $7.00 to $5.00 and set an “overweight” rating for the company in a research report on Tuesday, November 5th.

Cellectis Price Performance

Shares of NASDAQ CLLS opened at $1.64 on Monday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.78 and a current ratio of 1.78. The stock has a market cap of $91.16 million, a PE ratio of -1.26 and a beta of 3.09. Cellectis has a fifty-two week low of $1.53 and a fifty-two week high of $3.73. The stock has a fifty day moving average of $1.88 and a 200-day moving average of $2.06.

Cellectis (NASDAQ:CLLS) last announced its earnings results on Monday, November 4th. The biotechnology company reported ($0.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.03). Cellectis had a negative net margin of 234.39% and a negative return on equity of 74.55%. The company had revenue of $18.05 million during the quarter, compared to analysts’ expectations of $5.00 million. During the same period in the prior year, the business earned ($0.31) earnings per share. Equities research analysts anticipate that Cellectis will post -0.46 earnings per share for the current year.

Institutional Investors Weigh In On Cellectis

Several institutional investors and hedge funds have recently modified their holdings of CLLS. XTX Topco Ltd purchased a new position in Cellectis during the 2nd quarter valued at about $29,000. First Affirmative Financial Network purchased a new stake in shares of Cellectis during the third quarter valued at approximately $45,000. Principal Financial Group Inc. increased its position in shares of Cellectis by 2.9% during the second quarter. Principal Financial Group Inc. now owns 437,000 shares of the biotechnology company’s stock valued at $817,000 after acquiring an additional 12,467 shares in the last quarter. Finally, Long Focus Capital Management LLC lifted its position in Cellectis by 2.9% in the 2nd quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company’s stock valued at $8,634,000 after acquiring an additional 130,000 shares in the last quarter. 63.90% of the stock is owned by hedge funds and other institutional investors.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.